Avexis Inc. is preparing for a David-and-Goliath showdown with Biogen Inc. and its partner, Ionis Pharmaceuticals Inc., after the FDA green-lighted the design of a pivotal trial for the upstart's gene therapy candidate, AVXS-101, in infants and children with spinal muscular atrophy (SMA) type 1.